Korro Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Korro Bio, Inc. (KRRO) on August 5, 2026. The filing primarily addresses a material definitive agreement entered into on August 5, 2026, and references financial results for the quarter ended June 30, 2026, which were announced via press release on August 6, 2026.
Key Financial Metrics and Capital Structure
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, or debt levels within the text of the 8-K; these details are contained in the referenced press release (Exhibit 99.1). However, the filing discloses the following capital structure changes effective immediately following the transaction:
- Common Stock Outstanding: 13,725,646 shares.
- Unexercised Pre-Funded Warrants: 4,148,836 shares.
- Transaction Details: Venrock Healthcare Capital Partners surrendered 1,000,000 shares of common stock for no consideration in exchange for 1,000,000 pre-funded warrants.
- Warrant Terms: Exercise price of $0.001 per share; no expiration date; exercisable immediately.
Material Changes
The primary material change is the exchange of 1,000,000 shares of common stock held by Venrock for an equivalent number of pre-funded warrants. This transaction was executed under an exemption from registration pursuant to Section 3(a)(9) of the Securities Act of 1933. The filing also notes the issuance of a press release regarding Q2 2026 financial results, though specific comparative financial data is not included in this document.
Guidance, Risks, and Contingencies
Ownership Limitations: The pre-funded warrants include a beneficial ownership limitation. Holders may not exercise warrants if doing so would result in beneficial ownership exceeding 9.99% of the outstanding common stock, unless the holder provides 61 days' notice to increase this threshold (up to 9.99%).
Management Commentary: The filing incorporates by reference a press release dated August 6, 2026, for operational results and management commentary. No specific guidance or risk factors are detailed within the text of this 8-K beyond the standard incorporation of exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash burn figures.
- Verify the full terms of the Exchange Agreement (Exhibit 10.1) and Pre-Funded Warrant (Exhibit 4.1) for additional covenants or conditions.
- Confirm the current cash position and runway based on the Q2 2026 results referenced in the press release.
- Monitor the impact of the 9.99% beneficial ownership limitation on future liquidity and potential warrant exercises by Venrock.